Nilsine Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$13.3M Buy
11,082
+7
+0.1% +$7.15K 0.92% 18
2026
Q1
$9.62M Buy
11,075
+881
+9% +$893K 0.75% 33
2025
Q4
$11M Buy
10,194
+461
+5% +$441K 0.95% 23
2025
Q3
$7.43M Sell
9,733
-2,420
-20% -$1.8M 0.67% 29
2025
Q2
$9.47M Sell
12,153
-35
-0.3% -$27.2K 0.96% 22
2025
Q1
$10.1M Buy
12,188
+272
+2% +$226K 1.1% 18
2024
Q4
$9.2M Buy
11,916
+600
+5% +$497K 0.98% 19
2024
Q3
$10M Sell
11,316
-78
-0.7% -$70.1K 1.3% 16
2024
Q2
$10.3M Buy
11,394
+17
+0.1% +$13.6K 1.38% 15
2024
Q1
$8.85M Buy
11,377
+812
+8% +$578K 1.21% 19
2023
Q4
$6.16M Buy
10,565
+241
+2% +$141K 0.95% 25
2023
Q3
$5.55M Sell
10,324
-142
-1% -$73.2K 0.84% 27
2023
Q2
$4.91M Hold
10,466
0.72% 33
2023
Q1
$3.59M Buy
+10,466
New +$3.53M 0.56% 50

Other funds holding LLY

Nilsine Partners's LLY Position: Q2 2026 in Review

Nilsine Partners increased its Eli Lilly (LLY) stake by 0.06% in Q2 2026, buying an estimated $7.15K and bringing the position to 11,082 shares worth $13.3M. The position accounts for 0.92% of the portfolio, ranked #18.

Nilsine Partners first reported a position in LLY in Q1 2023 and has held it in 14 quarters since. 1,558 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Nilsine Partners held 11,082 shares of Eli Lilly worth $13.3M as of Q2 2026.
  • Nilsine Partners bought 7 Eli Lilly shares in Q2 2026, an estimated $7.15K.
  • Eli Lilly made up 0.92% of Nilsine Partners's portfolio in Q2 2026, its #18 holding.
  • Nilsine Partners first reported a position in Eli Lilly in Q1 2023 and has held it in 14 quarters since.
  • 1,558 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Nilsine Partners's 13F filing for Q2 2026, filed 24 Jul 2026.